Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9WJR5
UPID:
POK19_HUMAN
Alternative names:
HERV-K(C19) Pol protein; HERV-K_19q11 provirus ancestral Pol protein
Alternative UPACC:
Q9WJR5; O15312
Background:
The Endogenous retrovirus group K member 19 Pol protein, also known as HERV-K(C19) Pol protein and HERV-K_19q11 provirus ancestral Pol protein, plays a crucial role in the early stages of viral infection. It converts viral RNA into double-stranded DNA, with its RNase H domain degrading the RNA template and removing the RNA primer. This protein is also involved in the integration of viral DNA into the host cell chromosome, a key step in viral replication.
Therapeutic significance:
Understanding the role of Endogenous retrovirus group K member 19 Pol protein could open doors to potential therapeutic strategies. Its involvement in the early stages of viral replication makes it a promising target for antiviral drug development.